Ocugen Q2 FY26 earnings call OCGN

Ocugen's modified gene therapy platform takes a gene-agnostic, multifactorial approach, designed to address the root cause of complex retinal diseases by modulating nuclear hormone receptors. This platform is being advanced across three late-stage programs: OCU400 for Retinitis Pigmentosa (RP), OCU410ST for Stargardt disease, and OCU410 for Geographic Atrophy (GA). These programs collectively target approximately 3 million patients in the US and Europe, representing a significant commercial opportunity. The company aims for three BLA filings by 2028, with a catalyst-rich window in H1 2027 for top-line data from OCU400 and OCU410ST.

The FDA cleared the Phase 3 Armada 3 trial for OCU410 in GA and granted RMAP designation. GA affects 2-3 million patients in the US and Europe, with current therapies only targeting one of four disease pathways. OCU410, by delivering RORA, addresses all four pathways simultaneously with a single subretinal injection. The Armada 3 trial is planned as a global study of approximately 237 subjects, using an adaptive design powered at 95% for the primary endpoint, with initiation planned by September 2026. Positive 12-month Phase 2 data showed a statistically significant 31% reduction in GA lesion growth and 27% preservation of the ellipsoid zone in the target patient population.

OCU410ST is designed to treat Stargardt disease, affecting 100,000 patients in the US and Europe, with no approved therapies. The Phase 2/3 Guardian trial completed enrollment and dosing of 63 participants. The trial includes a broad patient population, from early to late-stage and pediatric patients (3+ years), addressing about 1200 pathogenic mutations in the ABCA4 gene. Interim outcome decision for the first 50% of subjects is expected in Q3 2026, with top-line data in Q2 2027 and BLA submission mid-2027. Prior Phase 1 data showed slowing in structural progression and functional benefit, including visual function improvement.

The Phase 3 Limelight trial for OCU400 in RP has completed enrollment with 140 patients randomized 2:1 (treated vs. control). This trial is gene-agnostic, spanning over 30 genetic mutations, and includes pediatric patients. Top-line Phase 3 data is expected in Q1 2027, with potential approval in Q4 2027. FDA feedback confirmed the path to rolling BLA submission tied to the Q1 2027 data. Manufacturing process performance qualification (PPQ) batches are complete, supporting BLA and commercial launch supplies. A binding term sheet was signed with Root Pharmaceutical for exclusive rights in the MENA region.

Ocugen is building foundational commercial capabilities focusing on five key areas: discussions with CMS for market access and reimbursement, identifying specialized centers of excellence for treatment delivery, mapping the patient journey, assessing manufacturing and supply chain requirements, and building commercial infrastructure. Financially, the company's cash, cash equivalents, and restricted cash totaled $100.4 million as of June 30, 2026, following a $130 million convertible notes financing, extending the cash runway into 2028. Additional levers for capital include potential sale of the OCU410ST PRV and Janus Henderson warrants.